MISSING DATA IN CONFIRMATORY CLINICAL TRIALS

被引:19
作者
Flyer, Paul [1 ]
Hirman, Joseph [1 ]
机构
[1] Pacific NW Stat Consulting Inc, Dept Biostat, Woodinville, WA 98072 USA
关键词
Imputation; Intention to treat; LOCF; Missing at random; Missing data; Noncompliance; Repeated measures;
D O I
10.1080/10543400903242746
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Missing data for key efficacy and safety endpoints in clinical trials have the potential to undermine the scientific integrity of the study and prevent definitive conclusions regarding the safety and efficacy of an experimental product. Much of the missing data is the result of poor protocol design and a lack of agreement in the scientific community regarding the collection of study data after treatment discontinuation instead of an inability to collect the data. Rather than dealing with the fundamental causes of missing data, the statistical community has traditionally attempted to explicitly impute the missing data based upon observed data or more recently through the use of statistical models that implicitly impute the missing data. In this article, the causes for missing data are described and a number of approaches to maintain the integrity of the studies are described.
引用
收藏
页码:969 / 979
页数:11
相关论文
共 17 条
[1]  
[Anonymous], NOT GUID CLIN INV ME
[2]  
[Anonymous], GUID IND DIAB MELL D
[3]  
BHORE R, 2002, 2122621251 NDA FOOD
[4]  
Committee for medicinal products for human use (CHMP), 2008, GUID CLIN INV IMM SO
[5]  
DIXON C, 1999, 21083 NDA FOOD DRUG
[6]  
*FOOD DRUG ADM, 1990, GUID CLIN EV LIP ALT
[7]  
*FOOD DRUG ADM, 1998, GUID IND DEV ANT DRU
[8]  
*FOOD DRUG ADM, 2007, GUID IND CLIN TRIAL
[9]  
Food & Drug Administration, 2002, GUID IND ANT DRUGS U
[10]  
GABRY KE, 2005, 21733 NDA FOOD DRUG